<DOC>
	<DOCNO>NCT01485601</DOCNO>
	<brief_summary>The purpose study find optimal dose determine safety tolerability single dose MT10109 ( clostridium botulinum type A ) administer intramuscular injection subject glabellar line compare standard dose BOTOXÂ®</brief_summary>
	<brief_title>Safety Efficacy Study Botulinum Toxin Type A Treat Glabellar Lines</brief_title>
	<detailed_description />
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Adults age 18 75 year glabellar facial line least moderate severity maximum frown investigator 's assessment . Women childbearing potential must negative serum pregnancy test screening Patients inability substantially lessen glabellar line physically spread apart . Concurrent therapy , investigator 's opinion , would interfere evaluation safety efficacy study medication Patients anaphylactic response history botulinum toxin type A . Patients administer botulinum toxin type A within previous 6 month . Pregnant lactating woman . Participation research study involve drug administration within 90 day precede enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>